This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2018 Aug;15(8):468.

doi: 10.1038/s41585-018-0029-6.

[¹⁷⁷Lu]PSMA-617 radionuclide therapy shows promise

Conor A Bradley¹

Affiliations

PMID: 29789593
DOI: 10.1038/s41585-018-0029-6

Comment

[¹⁷⁷Lu]PSMA-617 radionuclide therapy shows promise

Conor A Bradley. Nat Rev Urol. 2018 Aug.

. 2018 Aug;15(8):468.

doi: 10.1038/s41585-018-0029-6.

Author

Conor A Bradley¹

Affiliation

¹ Nature Reviews Urology, . nruro@nature.com.

PMID: 29789593
DOI: 10.1038/s41585-018-0029-6

No abstract available

PubMed Disclaimer

Comment on

[¹⁷⁷Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study.
Hofman MS, Violet J, Hicks RJ, Ferdinandus J, Thang SP, Akhurst T, Iravani A, Kong G, Ravi Kumar A, Murphy DG, Eu P, Jackson P, Scalzo M, Williams SG, Sandhu S. Hofman MS, et al. Lancet Oncol. 2018 Jun;19(6):825-833. doi: 10.1016/S1470-2045(18)30198-0. Epub 2018 May 8. Lancet Oncol. 2018. PMID: 29752180 Clinical Trial.

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Nature Publishing Group
Other Literature Sources
- scite Smart Citations
Miscellaneous
- NCI CPTAC Assay Portal